IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 193 filers reported holding IMPAX LABORATORIES INC in Q3 2017. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $843,000 | -55.3% | 50,604 | -45.5% | 0.01% | -52.9% |
| Q3 2017 | $1,885,000 | +229.5% | 92,880 | +161.2% | 0.02% | +240.0% |
| Q2 2017 | $572,000 | -35.7% | 35,554 | -5.2% | 0.01% | -44.4% |
| Q3 2016 | $889,000 | -89.8% | 37,512 | -86.2% | 0.01% | -85.7% |
| Q1 2016 | $8,711,000 | -9.4% | 272,037 | +21.0% | 0.06% | -7.4% |
| Q4 2015 | $9,617,000 | +28.4% | 224,901 | +5.7% | 0.07% | +51.1% |
| Q3 2015 | $7,490,000 | +515.4% | 212,733 | +702.7% | 0.04% | +462.5% |
| Q2 2015 | $1,217,000 | +905.8% | 26,502 | +924.8% | 0.01% | +700.0% |
| Q1 2015 | $121,000 | -87.1% | 2,586 | -91.2% | 0.00% | -80.0% |
| Q4 2014 | $936,000 | +800.0% | 29,535 | +574.0% | 0.01% | +400.0% |
| Q3 2014 | $104,000 | -33.8% | 4,382 | -29.8% | 0.00% | 0.0% |
| Q4 2013 | $157,000 | -66.3% | 6,240 | -72.5% | 0.00% | -50.0% |
| Q3 2013 | $466,000 | – | 22,726 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 423,161 | $13,406,000 | 7.47% |
| Aravt Global | 2,300,000 | $72,864,000 | 5.43% |
| Slate Path Capital LP | 2,330,000 | $73,814,000 | 5.16% |
| Orbimed Advisors | 6,678,000 | $211,559,000 | 2.02% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Penn Capital Management Company, LLC | 709,045 | $22,463,000 | 0.94% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $7,920,000 | 0.79% |
| NEW AMSTERDAM PARTNERS LLC/NY | 276,169 | $8,749,000 | 0.76% |
| Matarin Capital Management, LLC | 52,932 | $1,676,886,000 | 0.74% |